FDA Approval And Anaphylm Launch Will Expand Global Reach

AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Published
31 Mar 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$8.42
53.2% undervalued intrinsic discount
24 Jul
US$3.94
Loading
1Y
15.9%
7D
0.3%

Author's Valuation

US$8.4

53.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 4.68%

Shared on24 Apr 25
Fair value Decreased 4.44%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 9.78%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25